| MLH1 -93 status | de novo AML (population 2A) (n = 420) | Controls (population 2B) (n = 952) | t-AML (population 1) | |||||||
| t-AML (%) (n = 96) | OR (95% CI) | Previous treatment | ||||||||
| Any chemotherapy (%) (n = 56) | OR (95% CI) | Methylating chemotherapy (%) (n = 12) | OR (95% CI) | Radiotherapy (%) (n = 40) | OR (95% CI) | |||||
| GG | 246 (63.1) | 585 (63.7) | 63 (65.6) | 1 | 35 (62.5) | 1 | 3 (25.0) | 1 | 28 (70.0) | 1 |
| GA | 128 (32.8) | 292 (31.8) | 30 (31.2) | 0.91(0.56 to 1.50) | 18 (32.1) | 0.99(0.54 to 1.83) | 7 (58.3) | 4.63(1.16 to 18.43) | 12 (30.0) | 0.67(0.31 to 1.45) |
| AA | 16 (4.1) | 41 (4.5) | 3 (3.1) | 0.85(0.23 to 3.08) | 3 (5.4) | 1.36(0.37 to 4.93) | 2 (16.7) | 10.68(1.61 to 71.04) | 0 | – |
| sna | 30 | 34 | – | – | – | – | ||||
| GG | 246 (63.1) | 585 (63.7) | 63 (65.6) | 1 | 35 (62.5) | 1 | 3 (25.0) | 1 | 28 (70.0) | 1 |
| GA+AA | 144 (36.9) | 333 (36.3) | 33 (34.4) | 0.91(0.56 to 1.47) | 21 (37.5) | 1.03(0.58 to 1.85) | 9 (75.0) | 5.31(1.40 to 20.15) | 12 (30.0) | 0.61(0.29 to 1.31) |
sna, sample not amplified; t-AML, therapy related AML.
Odds ratios and 95% confidence intervals were estimated by logistic regression using de novo AML cases (population 2A) as the reference population and adjusting for sex and age at diagnosis.